Carhart-Harris, R.L., Bolstridge, M., Rucker, J., Day, C.M.J., Watts, R., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J.A., Forbes, B., Nutt, D.J. (2017) Psychopharmacology , 235(2) , 399-408
Abstract
Six-month follow-up to the 2016 open-label feasibility study of psilocybin with psychological support in treatment-resistant depression. Depressive symptom reductions (e.g., QIDS, HDRS) observed acutely and at 3 months persisted in a substantial proportion of participants at 6 months, with some cases of partial or full relapse, highlighting both durability and limits of effect. No new serious adverse events emerged. Findings support further controlled trials and exploration of maintenance strategies (e.g., additional therapeutic integration or booster dosing).